Abstract: Sixth-generation (6G) mobile communication networks are expected to have dense infrastructures, large antenna size, wide bandwidth, cost-effective hardware, diversified positioning methods, ...

Abstract: Reliable and efficient trajectory generation methods are a fundamental need for autonomous dynamical systems. The goal of this article is to provide a comprehensive tutorial of three major ...

India-based Sun Pharmaceutical Industries Ltd is reportedly evaluating a potential acquisition of Organon & Co (NYSE: OGN), a U.S.-based women's healthcare company. If it goes through, the deal that ...

Clinical data support a 5-year duration for the Nexplanon implant, with no reported pregnancies during the extended 2-year study period. The Food and Drug Administration (FDA) has extended the ...

Organon & Co. OGN recently announced that the FDA has approved a supplemental New Drug Application, extending the duration of use of NEXPLANON (etonogestrel implant) 68 mg Radiopaque to up to five ...

— We have everything you need: full data on over 1 000 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & ...

Add Yahoo as a preferred source to see more of our stories on Google. The move is set to bolster and widen Organon’s US biosimilars immunology portfolio with multi-indication arthritis treatment.

Organon公司近日宣布，美国食品药品监督管理局(FDA)已批准避孕植入物Nexplanon®（依托孕烯植入剂）68毫克的补充新药申请，将3年的使用期限延长至5年。该药物适用于有生育潜力的女性用于预防怀孕。 Nexplanon是一种不透射线的、仅含孕激素、不含雄激素、柔软、可 ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the US ...

JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the US ...

The U.S. Food and Drug Administration (FDA) has approved a label expansion for Nexplanon to allow its manufacturer, Organon (OGN), to market the birth control implant, indicating an efficacy duration ...